These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 183135)

  • 21. Inhibition of platelet cyclic 3',5'-adenosine-monophosphate phosphodiesterases by pentifylline.
    Stefanovich V
    Arzneimittelforschung; 1975 May; 25(5):740-1. PubMed ID: 170944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of adenosine 3',5'-cyclic monophosphate phosphodiesterase in Daphne genkwa Sieb. et Zucc.
    Nikaido T; Ohmoto T; Sankawa U
    Chem Pharm Bull (Tokyo); 1987 Feb; 35(2):675-81. PubMed ID: 3036384
    [No Abstract]   [Full Text] [Related]  

  • 23. Eudistomin derivatives, novel phosphodiesterase inhibitors: synthesis and relative activity.
    Kobayashi J; Taniguchi M; Hino T; Ohizumi Y
    J Pharm Pharmacol; 1988 Jan; 40(1):62-3. PubMed ID: 2896779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism by which psychotropic drugs inhibit adenosine cyclic 3',5'-monophosphate phosphodiesterase of brain.
    Levin RM; Weiss B
    Mol Pharmacol; 1976 Jul; 12(4):581-9. PubMed ID: 183095
    [No Abstract]   [Full Text] [Related]  

  • 25. Cyclic nucleotide phosphodiesterase in heart and aorta of spontaneously hypertensive rats.
    Sharma RV; Bhalla RC
    Biochim Biophys Acta; 1978 Oct; 526(2):479-88. PubMed ID: 214127
    [No Abstract]   [Full Text] [Related]  

  • 26. Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy.
    Chiu WC; Kedem J; Weiss HR; Tse J; Cheinberg BV; Scholz PM
    Cardiovasc Res; 1994 Sep; 28(9):1360-5. PubMed ID: 7954646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concanavalin A ibhibition of liver plasma membrane-bound cyclic AMP-phosphodiesterase.
    Luly P; Scapin S; Ferretti E; Tomasi V
    FEBS Lett; 1976 Apr; 64(1):209-13. PubMed ID: 178544
    [No Abstract]   [Full Text] [Related]  

  • 28. Studies on the effect of nicotinamide and ethylnicotinic acid on cyclic AMP phosphodiesterase from rat liver.
    Hoshi Y
    Bull Osaka Med Sch; 1975 Oct; 21(2):77-91. PubMed ID: 181108
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhibition of adenosine 3',5'-cyclic monophosphate phosphodiesterase by nicotinic acid [proceedings].
    Saeed SA; Butt NM; Lovely JR; Collier HO
    Biochem Soc Trans; 1979 Oct; 7(5):1042-4. PubMed ID: 229022
    [No Abstract]   [Full Text] [Related]  

  • 30. The influence of nicergoline on reaction kinetics of various forms of cyclic AMP phosphodiesterase.
    Pericin D; Leskovac V
    Arzneimittelforschung; 1981; 31(12):2082-5. PubMed ID: 6277342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of motility in immature bovine spermatozoa by cyclic AMP phosphodiesterase inhibitors and seminal plasma.
    Hoskins DD; Hall ML; Munsterman D
    Biol Reprod; 1975 Sep; 13(2):168-76. PubMed ID: 177102
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of 2-(4-benzyl-piperidino)-1-(4-hydroxyphenyl)-1-propranolol on adenylate cyclase and 3,5'-cyclic AMP phosphodiesterase in vitro.
    Yamashita Y; Kawai M; Hotta K
    Jpn J Pharmacol; 1976 Jun; 26(3):391-4. PubMed ID: 185445
    [No Abstract]   [Full Text] [Related]  

  • 33. [Inhibition of rat heart and brain cyclic 3',5'-adenosine monophosphate phosphodiesterase under the influence of neurohormone "C"].
    Galoian AA; Gurvits BIa; Pogosian MA
    Vopr Biokhim Mozga; 1976; 11():89-96. PubMed ID: 203105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative structure-activity relationships for the inhibition of heart and brain cyclic AMP phosphodiesterases by some phenylbutenolides.
    Duperray B; Nemoz G; Prigent AF; Pacheco H
    Biochem Pharmacol; 1980 Jan; 29(1):115-8. PubMed ID: 6244825
    [No Abstract]   [Full Text] [Related]  

  • 35. Trapidil derivatives as potent inhibitors of cyclic AMP phosphodiesterase from heart and coronary arteries.
    Bartel S; Tenor H; Krause EG
    Biomed Biochim Acta; 1985; 44(5):K31-5. PubMed ID: 2415118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of [N-(2-oxo-3,5,7-cycloheptatrien-1-yl)] aminooxoacetic acid ethyl ester (AY-25,674) on cyclic 3',5'-nucleotide formation and phosphodiesterase activity.
    Pugsley TA; Lippmann W
    Experientia; 1979 Jan; 35(1):88-90. PubMed ID: 217716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo inhibitory effects of propentofylline on cyclic AMP phosphodiesterase activity.
    Nagata K; Ogawa T; Omosu M; Fujimoto K; Hayashi S
    Arzneimittelforschung; 1985; 35(7):1034-6. PubMed ID: 2996562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of epinephrine and cyclic AMP phosphodiesterase inhibitors on the glycogen synthetic pathway and glucose content in skeletal muscle.
    Haugaard ES; Davidheiser S; Haugaard N
    Biochem Pharmacol; 1976 Feb; 25(4):439-45. PubMed ID: 181002
    [No Abstract]   [Full Text] [Related]  

  • 39. Tissue and species specificity of cardiac cAMP-phosphodiesterase inhibitors.
    Pang DC
    Adv Second Messenger Phosphoprotein Res; 1992; 25():307-20. PubMed ID: 1313264
    [No Abstract]   [Full Text] [Related]  

  • 40. Interaction of amoscanate with the cyclic AMP-phosphodiesterases from Schistosoma mansoni, Onchocerca volvulus and bovine heart.
    Walter RD; Albiez EJ
    Tropenmed Parasitol; 1984 Jun; 35(2):78-80. PubMed ID: 6087521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.